Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) EPS (Weighted Average and Diluted) (2024 - 2026)

Maze Therapeutics' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.45 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 60.87% to -$0.45 in Q1 2026 year-over-year; TTM through Mar 2026 was -$2.48, a 74.17% increase, with the full-year FY2025 number at -$3.05, down 344.0% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.45 in Q1 2026 for Maze Therapeutics, up from -$0.6 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for MAZE hit a ceiling of $3.22 in Q2 2024 and a floor of -$13.91 in Q1 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$2.89 across 3 years, with a median of -$0.77 in 2025.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 93.56% in 2025, down 123.91% in 2025.
  • Tracing MAZE's EPS (Weighted Average and Diluted) over 3 years: stood at -$1.42 in 2024, then soared by 57.75% to -$0.6 in 2025, then grew by 25.0% to -$0.45 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for MAZE at -$0.45 in Q1 2026, -$0.6 in Q4 2025, and -$0.66 in Q3 2025.